Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes entered a licensing deal with LifeNet Health for the bio-implant maker’s new cellular allograft.
Virginia Beach, Va.-based LifeNet works with organ donation and tissue banking services, along with bio implants. The cellular allograft will be used for spinal fusion by DePuy Synthes’ spinal division, according to a press release.
“Our clinical, sales and marketing teams are energized by this new collaboration that will offer clinicians a new technology for treating spine patients," DePuy Synthes Spine president Max Reinhardt said in prepared remarks. "We are excited to collaborate with LifeNet Health and our colleagues in DePuy Synthes Biomaterials to enhance our product offering with biomaterials that complement and augment our spine portfolio."
Codman Neuro, a division of DePuy Synthes, recently had its recall upgraded to high risk Class I. The recall is for the Trufill n-BCA liquid embolic system, which was recalled in October 2013, due to an error in the instructions for use, which gave the wrong mixing ratio.
